Financial comparisons GC Genome Corporation
Stocks
A340450
KR7340450006
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,860.00 KRW | +0.21% |
|
-8.82% | -28.74% |
| 12-09 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 12/06/25 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 2.31B | -9.03% | -13.44% | -14.32% | -10.26% | 3.74x | |
| 13.95B | 6.28% | 14.35% | 16.52% | 7.49% | 2.1x | |
| 6.32B | 5.32% | 9.43% | 6.32% | 3.33% | 1.63x | |
| 2.04B | -0.91% | 3.04% | - | - | 1.07x | |
| 288M | 19.79% | 22.49% | 24.22% | 18.83% | -1.45x | |
| 428M | -4.92% | 9.66% | - | - | - | |
| 862M | -2.87% | -2.15% | -2.51% | -1.73% | -4.19x | |
| 1.44B | 0.44% | 2.79% | 0.68% | 0.7% | 0.58x | |
| 1.51B | 7.39% | 14.73% | 11.91% | 4.66% | 1.46x | |
| 79.74M | 21% | 29.74% | 19.7% | - | -0.85x | |
| 727M | -14.85% | -15.93% | 1.71% | - | - | |
| 156M | 10.89% | 14.6% | 11.95% | - | -0.11x | |
| 1.56B | 2.76% | 1.93% | 5% | 1.04% | 1.01x | |
| 607M | -37.19% | -19.34% | -17.14% | -10.92% | 0.19x | |
| 88.42M | 19.67% | 24.54% | 29.61% | - | - | |
| 956M | 4.37% | 6.54% | 4.9% | 5.72% | - | |
| 316M | 7.56% | 8.76% | 6.49% | 4.36% | - | |
| 3.6M | -298.73% | -302.59% | -86.14% | -76.86% | 0.73x | |
| 411M | 0.77% | 11.16% | 6.35% | 2.91% | 2.29x | |
| Average | 1.79B | -13.8% | -9.46% | 1.49% | -3.9% | 0.59x | |
| Weighted average by Cap. | 5.13B | -2.65% | -0.73% | 0.36% | -1.93% | 2.24x |
- Stock Market
- Stocks
- A340450 Stock
- Sector GC Genome Corporation
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
